BeiGene has officially launched its PD-1 cancer drug Tevimbra in the U.S. more than six months after receiving a much-delayed ...

As Sanofi continues to clean out its medicine chest, Italy’s Recordati is getting in on the action. | Recordati is floating ...

On the same day as Roche's Pharma Day in London, the biopharma giant revealed a high-dollar deal with Chinese-American ...

Since the introduction of the BIOSECURE Act in January, named companies and U.S.-based biopharmas alike have speculate | This ...

Armed with what it sees as impressive clinical data and bolstered by long-standing ties to the Niemann-Pick disease type C ...

While Mounjaro was cleared for use in England last year, Lilly put its launch on hold until its pre-filled injection device, ...

Eli Lilly’s juggernaut diabetes and obesity drugs Mounjaro and Zepbound have been erased from the FDA’s shortage list, ...

Hot on the tail of AstraZeneca’s Imfinzi, Bristol Myers Squibb’s PD-1/L1 inhibitor Opdivo has expanded its non-small cell lung cancer (NSCLC) net with an ...

With a recently acquired FDA nod for its Halozyme Therapeutics-partnered Vyvgat Hytrulo, argenx is looking to take Halozyme’s ...

After unlocking commercial supply and enlisting a manufacturing partner earlier this year, Ferring Pharmaceuticals has ...

As the BIOSECURE Act works its way through the U.S. legislative branch, two companies named in the bill are reportedly ...

For the biotech formerly known as Eliem Therapeutics, it’s all about the climb—Climb Bio, that is. | For the biotech formerly ...